TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Post-load CBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: disc space height of the cranial adjacent segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detrusor pressure at maximum urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: parental distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: problematic child behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of men with presumed early recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total:HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in anxiety ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insulin initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Barriers to encouraging patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort level during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of RV function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pausing patterns during language production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral aspects of autism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recuperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprocedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemarthroses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC of rupatadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessments (treatment related side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Partial clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly drinking quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak drinking quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of drinking to intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HR ≤65 beats/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedural convenience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effective radiation dose
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: objectively measured health behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) rate plus CRp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative patient satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV‐1 RNA < 400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid secretion after oral liquid meal intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: local/regional tumor control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: normal tissue complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Achieving a goal LDL <100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in fixation losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in localization error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dysphagia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects leading to discontinuation of study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal Clinically Important Difference (MCID) for improvement on CAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Clinically Important Difference (MCID) for deterioration on CAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Clinically Important Difference (MCID) for improvement on SGRQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Clinically Important Difference (MCID) for deterioration on SGRQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: body flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean center point thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean macular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in hearing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for amprenavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (C(max)) for amprenavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficiency of amoxicillin-clavulanate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isolation of bacterial pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma levels of interleukin-1 beta, TNF-alpha, and interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression levels of IL-1 beta, TNF-alpha, and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sex hormone binding globulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall sexual function (IIEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concavity measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recession reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycologic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anterior knee pain
Endpoint domain: Adverse events/effects
Primary endpoint: Lysholm knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physiologic performance of silicone-hydrogel lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective performance rating of silicone-hydrogel material
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: investigator satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: local reactions (redness, pain, swelling)
Endpoint domain: Adverse events/effects
Primary endpoint: Bronchial hyperresponsiveness (BHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of life (AQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year local-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbopelvic pain prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Indication of suicide as the most probable reason for the delay
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: central blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time to RTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intramuscular increased signal intensity on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinjuries recorded
Endpoint domain: Adverse events/effects
Primary endpoint: High-sensitivity C-reactive protein (hsCRP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalisation for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Median UIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tg concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with HbA1c levels ≤ 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Costs of anesthetic and nonanesthetic drugs and disposables
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean rate of decline of the ALSFRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malaria incidence
Endpoint domain: Mortality/survival
Primary endpoint: reduced substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient engagement in 12-Step groups
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: composite measure of doubling of serum creatinine, end stage renal disease or death
Endpoint domain: Mortality/survival
Primary endpoint: Thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum thyroglobulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: treatment completion
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Plasma vitamin E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in carotid intima-media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean amplitude of glycemic excursions (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regression of AT and IM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: I-QOL total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of catheter-related sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: biochemical disease‐free survival (bNED control)
Endpoint domain: Mortality/survival
Primary endpoint: distant metastases failure (DMF)
Endpoint domain: Mortality/survival
Primary endpoint: cause‐specific failure (CSF)
Endpoint domain: Mortality/survival
Primary endpoint: Angular measurements (SNA, FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear measurement (Pg to NB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of attempts for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-intubation complications
Endpoint domain: Adverse events/effects
Primary endpoint: Relative decrease in BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement/stabilization in behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of PCDDs, DLPCBs, and PCBs in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WAI (uNTx/Cr) at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding of WHO grade 2, 3, or 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates at 168 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4 cell counts increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total discontinuations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Enrollment rate of women
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nonparticipation due to patient-oriented factors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lower microbial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative levels of IL-6 and TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phagocytosis and respiratory burst after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete resolution of the infective process
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of symptoms (functional limitation, pain, tumefaction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of body temperature to within normal limits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stopping bleeding within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of bleeding and spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of serum calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma PTH from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual Acuity (VA) letter gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vascular and nonvascular deaths
Endpoint domain: Mortality/survival
Primary endpoint: stroke severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Energy intake from ad libitum meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Habitual energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients reporting asthma-related ED, urgent care, or hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of patients with 'in control' asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to asthma management guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Injection site induration
Endpoint domain: Adverse events/effects
Primary endpoint: Ulceration
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of new BILAG A/B flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with BILAG A flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with physician-assessed flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harris Hip Scores (HHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time taken to start partial and total weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-pertussis toxin antibody booster response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: seroprotective anti-tetanus and diphtheria antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: frequencies of solicited local adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: plasma Hcy concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentrations of vit‐B12 and folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve of plasma concentration versus time (ABC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of watery stool evacuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of days with diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VAS score for pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine dosage administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients referred for CT imaging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of NERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mastery of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Outcome of movement disorders (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal hip flexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximal knee flexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: knee valgus reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient satisfaction at 90 days post-procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean time spent in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Tolerance of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in cervical whiplash symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of cognitive strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Length of withdrawal bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Stability Quotient (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Consistent condom use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of Neisseria gonorrhoeae and Chlamydia trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tolerance of nCPAP
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes